# GPRC5D

Source: https://onco.cc/targets/gprc5d/  
OnCo record `gprc5d` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.

## Summary

GPRC5D is an orphan class C G-protein-coupled receptor expressed on myeloma cells and on hard keratinised tissue (skin, nails, tongue), which explains the characteristic skin, nail and taste toxicity of drugs directed against it. Expression is high in roughly 60 to 80 percent of myeloma cases and correlates with high-risk disease. Because it is independent of BCMA, it offers a second surface address for patients whose disease has escaped BCMA-directed therapy. Talquetamab, a GPRC5D×CD3 bispecific, is approved; a GPRC5D CAR-T (arlocabtagene autoleucel) is in phase 3. Open questions are how to sequence GPRC5D and BCMA agents and whether antigen loss limits durability. For a newcomer: it is the backup target used when BCMA-directed myeloma drugs stop working.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: t-cell-engager-target
- Symbol: GPRC5D
- Class: surface-antigen
- Biology: GPRC5D is an orphan class C GPCR.
- Where found: Multiple myeloma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/GPRC5D
- Wikipedia: https://en.wikipedia.org/wiki/GPRC5D

## Connected records

- biomarkers: [GPRC5D expression](https://onco.cc/biomarkers/gprc5d-expression/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Arlocabtagene Autoleucel](https://onco.cc/drugs/arlocabtagene-autoleucel/), [Talquetamab](https://onco.cc/drugs/talquetamab/)
- pairings: [BCMA-directed therapy → GPRC5D-directed therapy](https://onco.cc/pairings/bcma-then-gprc5d/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- people: [Ajai Chari](https://onco.cc/people/ajai-chari/)
- ideas: [Plan the second CAR-T target before the first one is lost](https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/)
- collections: [Multiple Myeloma Research Foundation (MMRF)](https://onco.cc/collections/mmrf/)
- key papers: [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/)
- institutions: [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/)

---
JSON: https://onco.cc/api/v1/entities/gprc5d.json